8 completed, 5 recruiting, 2 not yet recruiting, 2 unknown. 7 Phase 1, 7 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Primary Myelofibrosis (PMF): new trials by email Literature Review of Primary Myelofibrosis (PMF) trials Research Report on Primary Myelofibrosis (PMF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Peri-Transplant Gecacitinib - Myelofibrosis, Primary Myelofibrosis (PMF) | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 46 | 2026-11-01 | 2026-10-29 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-11-06 |
| Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm Myeloproliferative Neoplasm (MPN), Polycytemia Vera | Recruiting | Université Catholique de Louvain | 150 | 2026-05-01 | 2026-05-15 | |
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 100 | 2026-04-29 | 2026-10-29 |
| Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis Pelabresib, Ruxolitinib - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 3 | 2026-04-15 | 2026-09-09 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis Ropeginterferon alfa-2b (BESREMi®) - Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) | Phase 2 | Recruiting | The University of Hong Kong | 20 | 2025-03-01 | 2025-06-11 |
| Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis Primary Myelofibrosis (PMF), Healthy Subjects | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 70 | 2023-11-14 | 2026-01-06 | |
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis KRT-232, TL-895 - Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Phase 2 | Unknown | Kartos Therapeutics, Inc. | 52 | 2021-04-13 | 2022-05-09 |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis PXS-5505 - Myelofibrosis, Primary Myelofibrosis (PMF) | Phase 1 / Phase 2 | Completed | Syntara | 43 | 2021-02-18 | 2026-08-04 |
| Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis Jaktinib hydrochloride tablets - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 51 | 2020-01-07 | 2023-04-20 |
| Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib PU-H71 - Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Phase 1 | Terminated | Samus Therapeutics, Inc. | 11 | 2019-08-12 | 2022-11-17 |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF) | Phase 2 / Phase 3 | Unknown | Kartos Therapeutics, Inc. | 385 | 2019-01-15 | 2023-04-28 |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Bomedemstat - Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 1 / Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 90 | 2017-07-18 | 2024-01-10 |
| Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) MMB - Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis | Phase 2 | Completed | Sierra Oncology LLC - a GSK company | 41 | 2016-01-29 | 2023-06-18 |
| Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Momelotinib, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 156 | 2014-06-19 | 2023-05-23 |
| Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) INC424 - Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF) | Phase 4 | Completed | Novartis Pharmaceuticals | 48 | 2012-05-01 | 2015-03-03 |
| Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases AZD1480 - Primary Myelofibrosis (PMF), Post-Polycythaemia Vera | Phase 1 | Completed | AstraZeneca | 65 | 2009-05-01 | 2017-04-24 |
| Managed Access Programs for INC424, Ruxolitinib Ruxolitinib - Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) | Available | Novartis Pharmaceuticals | 2025-11-18 |
Primary Myelofibrosis (20) · Myeloproliferative Disorders (4) · Polycythemia Vera (3) · Thrombocythemia, Essential (3) · Blast Crisis (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Bone Marrow Neoplasms (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Hemorrhagic Disorders (1) · Inflammation (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
Hematologic Diseases (20) · Hemic and Lymphatic Diseases (20) · Bone Marrow Diseases (19) · Myeloproliferative Disorders (16) · Neoplasms (4) · Neoplasms by Site (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Bone Marrow Neoplasms (2) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Neoplasms (2) · Hemorrhagic Disorders (2)
ruxolitinib (4) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (2) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (2) · 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- (1) · AZD 1480 (1) · bomedemstat (1) · imetelstat (1)
Novartis Pharmaceuticals (4) · Kartos Therapeutics, Inc. (2) · Sierra Oncology LLC - a GSK company (2) · AstraZeneca (1) · First Affiliated Hospital of Zhejiang University (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (1) · MPN Research Foundation (1) · Prelude Therapeutics Incorporated (1) · Samus Therapeutics, Inc. (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Syntara (1) · The University of Hong Kong (1) · University of Wisconsin, Madison (1) · Université Catholique de Louvain (1)
United States (12) · Italy (6) · Australia (5) · France (5) · Canada (4) · Germany (4) · Spain (4) · United Kingdom (4) · Poland (3) · South Korea (3) · Taiwan (3) · Argentina (2) · Belgium (2) · Brazil (2) · Bulgaria (2)
Becker Hewes, MD (1) · Harinder Gill, MD (1) · Hongtao Liu, MD, PhD (1) · Jana Baskar, MBBS MMedSc MBA (1) · Jie Jin, MD (1) · Michael Silverman, M.D. (1) · Raajit Rampal, MD, PhD (1) · Ronald Hoffman, MD (1) · Srdan Verstovsek, MD (1) · Vincent Ribrag, MD (1)
PMID 39516087, PMID 29275119, PMID 37042865, PMID 38990433, PMID 39061196, PMID 40241543, PMID 40535755, PMID 41758981, PMID 41958363, PMID 42054549
2018 (1), 2025 (1)